What is the best medication regimen for a patient with metabolic dysfunction-associated steatotic liver disease (MASLD) who has hypercholesterolemia and hypertriglyceridemia?

Best Medicine for MASLD with Hypercholesterolemia and Hypertriglyceridemia

For MASLD patients with hypercholesterolemia and hypertriglyceridemia, statins are the first-line therapy for cardiovascular risk reduction, while fibrates (pemafibrate or fenofibrate) should be added for severe hypertriglyceridemia (triglycerides >500 mg/dL) to prevent pancreatitis; neither directly treats the liver disease itself, but both are safe in non-cirrhotic MASLD.

Lipid Management Strategy

For Hypercholesterolemia (Primary Target)

Statins are the cornerstone therapy for patients with MASLD and hypercholesterolemia 1. The 2024 EASL-EASD-EASO guidelines emphasize that cardiovascular disease is the leading cause of death in MASLD patients, making aggressive lipid management critical 2.

• Statins are safe in compensated cirrhosis and may actually improve outcomes including reduced decompensation, hepatocellular carcinoma risk, and mortality 1
• Avoid statins in decompensated cirrhosis unless cardiovascular benefits clearly outweigh risks 1
• Statins do not worsen liver disease and should not be withheld due to MASLD diagnosis alone

For Hypertriglyceridemia (Secondary Target)

Fibrates are safe and effective for managing hypertriglyceridemia in MASLD patients:

Pemafibrate (Preferred if Available)

• Significantly improves ALT levels in MASLD patients with hypertriglyceridemia, with effects visible at 3 months and sustained through 12 months 3
• ALT normalization rates increased from 30.4% to 56.6% over 12 months in a large multicenter study 3
• Provides robust triglyceride lowering while being liver-neutral 4

Fenofibrate (Alternative)

• MASLD-neutral with excellent triglyceride-lowering properties 5
• Comparable liver enzyme changes to other active treatments (atorvastatin, omega-3 fatty acids) 5
• Safe reassuring profile in MASLD patients 5

Use fibrates when:

• Triglycerides >500 mg/dL (to prevent pancreatitis)
• Persistent hypertriglyceridemia despite statin therapy
• Mixed dyslipidemia requiring dual therapy

MASLD-Specific Liver Therapy Considerations

Current Approved Options

Resmetirom is the only MASH-targeted therapy with strong guideline support for non-cirrhotic patients with significant fibrosis (stage ≥2) 2. However, this addresses liver histology, not lipids directly.

Metabolic Agents (Use for Their Primary Indications)

GLP-1 receptor agonists should be used if the patient has:

• Type 2 diabetes
• Obesity (BMI ≥30 or ≥27 with comorbidities)

These agents improve cardiometabolic outcomes and are safe in MASLD, including compensated cirrhosis 2. While not approved as MASH-targeted therapy, substantial weight loss from GLP-1 RAs provides hepatic histological benefit 2.

SGLT2 inhibitors or metformin should be used for:

• Type 2 diabetes
• Heart failure
• Chronic kidney disease

These are safe in MASLD and should be prescribed for their respective indications 2.

Practical Treatment Algorithm

Step 1: Assess Fibrosis Stage

• Non-cirrhotic MASLD: All lipid-lowering agents are safe
• Compensated cirrhosis: Statins and fibrates remain safe
• Decompensated cirrhosis: Avoid statins; use fibrates with caution

Step 2: Prioritize by Lipid Pattern

1. Elevated LDL-C: Start moderate-to-high intensity statin
2. Triglycerides >500 mg/dL: Add fibrate (pemafibrate preferred, fenofibrate alternative)
3. Triglycerides 200-499 mg/dL: Consider fibrate if cardiovascular risk is high or after statin optimization

Step 3: Add Metabolic Agents Based on Comorbidities

• If diabetic or obese: Add GLP-1 RA (semaglutide now approved for MASH with fibrosis)
• If diabetic with heart failure/CKD: Add SGLT2 inhibitor
• If non-cirrhotic MASH with fibrosis ≥F2: Consider resmetirom if locally approved

Step 4: Monitor Response

• Lipid panel: Every 3-6 months until at goal
• Liver enzymes: Every 3-6 months (expect improvement with pemafibrate)
• Fibrosis assessment: Annually with non-invasive tests (elastography, FIB-4)

Critical Caveats

Do not withhold statins due to elevated liver enzymes in MASLD patients—this is a common error. Statins are safe and necessary for cardiovascular protection 1.

Vitamin E and pioglitazone are NOT recommended as MASH-targeted therapies despite historical use, due to lack of robust phase III trial evidence and potential long-term risks 2.

No pharmacotherapy is currently recommended for cirrhotic-stage MASH from a liver-specific standpoint, but lipid management for cardiovascular protection remains essential 2.

Metformin can be used in compensated cirrhosis with preserved renal function but must be avoided in decompensated cirrhosis due to lactic acidosis risk 2.

Bottom Line

The optimal regimen combines statin therapy for hypercholesterolemia with fibrate therapy for significant hypertriglyceridemia, both of which are safe in MASLD and address the primary cause of mortality (cardiovascular disease) in this population. Add GLP-1 RAs or SGLT2 inhibitors based on metabolic comorbidities, as these provide additional cardiometabolic benefits while being liver-safe. This approach prioritizes mortality and quality of life through aggressive cardiovascular risk reduction while avoiding harm to the liver.